NASDAQ: BJDXBluejay Diagnostics Inc Stock
$0.55+0.00 (+0%)
Updated Apr 25, 2024
BJDX Price
$0.55
Fair Value Price
$1.68
Market Cap
$1.48M
52 Week Low
$0.47
52 Week High
$13.98
P/E
-0.06x
P/B
0.51x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$9.95M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.68
Operating Cash Flow
-$8M
Beta
0.9
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BJDX Overview
Bluejay Diagnostics, Inc. manufactures products for triage, diagnosis, and monitoring of disease progression. Offerings include minimally-invasive point-of-care diagnostics tests and devices that provide patients and providers with access to affordable and timely healthcare. Its focus is on the infectious disease, inflammation, and oncology markets. Bluejay Diagnostics was founded in 2015 and is headquartered in Acton, MA.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BJDX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BJDX ($0.55) is undervalued by 67.14% relative to our estimate of its Fair Value price of $1.68 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
BJDX ($0.55) is significantly undervalued by 67.14% relative to our estimate of its Fair Value price of $1.68 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
BJDX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BJDX due diligence checks available for Premium users.
Be the first to know about important BJDX news, forecast changes, insider trades & much more!
BJDX News
Valuation
BJDX fair value
Fair Value of BJDX stock based on Discounted Cash Flow (DCF)
Price
$0.55
Fair Value
$1.68
Undervalued by
67.20%
BJDX ($0.55) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BJDX ($0.55) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BJDX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BJDX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.06x
Industry
29.73x
Market
40.97x
BJDX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.51x
Industry
3.71x
BJDX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BJDX's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.3M
Profit Margin
0%
BJDX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$4.9M
Liabilities
$2.0M
Debt to equity
0.68
BJDX's short-term assets ($3.22M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BJDX's short-term assets ($3.22M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BJDX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.8M
Investing
-$87.9k
Financing
-$3.1k
BJDX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BJDX vs Medical Device Stocks
Bluejay Diagnostics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.